Ascletis PharmaASCLF -4.00%38 Cash Ratio is 14.90 as of Dec. 2025, which is 24% below its 10-year median of 19.65. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,386 Biotechnology companies, Ascletis Pharma ranks better than 88.17% on this metric.
Ascletis Pharma has a Cash Ratio of 14.90. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Ascletis Pharma's Cash Ratio or its related term are showing as below:
ASCLF'
s Cash Ratio Range Over the Past 10 Years
Min: 5.78 Med: 19.65 Max: 36.79
Current: 14.9
During the past 10 years, Ascletis Pharma's highest Cash Ratio was 36.79. The lowest was 5.78. And the median was 19.65.
ASCLF's Cash Ratio is ranked better than 88.17% of 1386
companies
in the Biotechnology industry
Industry Median: 2.93
vs ASCLF: 14.90
Ascletis Pharma (OTCPK:ASCLF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Ascletis Pharma Cash Ratio Related Terms
Ascletis Pharma Cash Ratio Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ascletis Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a Cash Ratio of 14.90 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Ascletis Pharma and its competitors. This is 24% below median its historical median of 19.65. Over the past decade, Ascletis Pharma's Cash Ratio has ranged from 5.78 to 36.79. According to the industry distribution chart, Ascletis Pharma ranks #164 out of 1386 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Ascletis Pharma's Cash Ratio too high?
Ascletis Pharma's current Cash Ratio of 14.90 is 24% below median its 10-year median of 19.65. Over the past 10 years, this metric has ranged from a low of 5.78 to a high of 36.79. The Biotechnology industry median Cash Ratio is 2.93. Ascletis Pharma's value of 14.90 is 408.5% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #164 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #164 out of 1386 companies for Cash Ratio. This places Ascletis Pharma in the top 12% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Ascletis Pharma's value of 14.90 is 408.5% above this benchmark. Historically, Ascletis Pharma's own Cash Ratio has ranged from 5.78 to 36.79 over the past decade. While the company's 10-year median is 19.65 vs. the industry median of 2.93, Ascletis Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Cash Ratio of 14.90 is 408.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Ascletis Pharma and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Cash Ratio is 14.90, which is 24% below median its own 10-year median of 19.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Cash Ratio is 14.90, which is 24% below median its 10-year median of 19.65 and 408.5% above the Biotechnology industry median of 2.93. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Cash Ratio is 14.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Cash Ratio: 14.90 (24% below median its 10-year median of 19.65)
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
Industry Position: 408.5% above the Biotechnology median (#164 of 1386)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
